Related Experiment Video

Updated: Jul 7, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

CD6 and Its Interacting Partners: Newcomers to the Block of Cancer Immunotherapies

Lucía Aragón-Serrano1, Laura Carrillo-Serradell1, Violeta Planells-Romeo1

  • 1Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Rosselló 149-153, 08036 Barcelona, Spain.

International Journal of Molecular Sciences
|December 23, 2023
PubMed

Insights

CD6, a receptor on immune cells, is a promising new target for cancer immunotherapy. Targeting CD6 offers innovative strategies for treating various blood and solid tumors.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Current cancer treatments need safer, more effective options.
  • Immunomodulatory receptors like CTLA-4 and PD-1 are key in cancer immunotherapy.
  • CD6, expressed on T cells, B cells, and NK cells, interacts with ligands overexpressed on cancer cells.

Purpose of the Study:

  • To review recent experimental evidence on CD6's role in cancer immunotherapy.
  • To explore innovative therapeutic strategies targeting CD6.

Main Methods:

  • Literature review of experimental evidence.
  • Analysis of diverse therapeutic strategies including monoclonal antibodies, decoy receptors, and CAR T-cell therapy.

Main Results:

  • CD6 and its ligands are overexpressed in various hematological and non-hematological malignancies.
  • CD6 presents a viable target for novel cancer therapies.
  • Innovative strategies targeting CD6 are being developed.

Conclusions:

  • CD6 is a promising therapeutic target for diverse cancers.
  • Targeting CD6 offers potential for more potent and safer cancer immunotherapies.
  • Further research into CD6-based strategies is warranted.
Keywords:
CD166/ALCAMCD318/CDCP1CD44CD6adoptive cell transfercancerchimeric antigen receptordecoy receptorimmunotherapymonoclonal antibodiesscavenger receptors

More Related Videos

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.6K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
741
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
923
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
370
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K